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Background: ProveblueW, a methylene blue dye that complies with European Pharmacopoeia and contains limited
organic impurities and heavy metals of recognized toxicity, showed in vitro synergy against Plasmodium falciparum
when combined with atorvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl-Coenzyme A reductase. The objective
of this study was to evaluate the in vivo efficacy of ProveblueW when combined with atorvastatin in a murine
model of experimental cerebral malaria.
Methods: Forty female C57Bl6/N mice were divided into four groups (control, atorvastatin 40 mg/kg for seven
days, ProveblueW 10 mg/kg for five days and atorvastatin combined with ProveblueW), infected with Plasmodium
berghei ANKA parasites by intraperitoneal inoculation and observed for 45 days.
Results: Treatment with atorvastatin alone did not demonstrate an effect significantly different from no treatment
(p = 0.0573). All the mice treated by atorvastatin alone died. Treatment with ProveblueW or a combination of
ProveblueW and atorvastatin was significantly increased survival of cerebral malaria (p = 0.0011 and 0.0002,
respectively). Although there was only one death in the atorvastatin and ProveblueW combination treatment group
(10%) versus two deaths (22%) with ProveblueW treatment, the effect on cerebral malaria was not significant
(p = 0.283).
Conclusions: The present work demonstrated, for the first time, the high efficacy of ProveblueW in preventing
cerebral malaria. Atorvastatin alone or in combination appears to possess limited use for preventing cerebral
malaria. Combination of atorvastatin with lower doses of ProveblueW (<10 mg/kg/day) should be evaluated to
show potential synergistic effects in cerebral malaria prevention.
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In 2002, the World Health Organization (WHO) re-
commended that artemisinin-based combination therapy
(ACT) should be used for all cases of uncomplicated
malaria. Four years later, the WHO further recommen-
ded that artesunate should be deployed as the first-line
treatment for severe malaria in adults and replace qui-
nine due to its efficacy and better tolerance [1]. In 2010,* Correspondence: bruno.pradines@free.fr
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reproduction in any medium, provided the ora large-scale trial confirmed the potency of artesunate
for treating severe malaria in children [2]. In 2011,
WHO recommended artesunate as the first-line treat-
ment for severe malaria. Several recent studies have repor-
ted clinical failures or extended parasite clearance times in
Cambodia [3-5].
There is an urgent need for the discovery of new anti-
malarial drugs and combination therapy. A combinato-
rial approach protects each drug from the development
of resistance and reduces the overall transmission rate of
malaria [6].
Methylene blue (MB) is an old anti-malarial drug that
is no longer in use. In 1891, Guttmann and Ehrlich
were the first to report the anti-malarial properties of al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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scribed the clinical cure of two patients after oral ad-
ministration of MB [7]. Cardamatis wrote in Progrès
Médical that he had found MB to be very effective in
the early stages of severe malaria cachexia in cases that
were resistant to quinine [8]. MB has shown in vitro ac-
tivity against Plasmodium falciparum strains [9,10] or
isolates [11,12] and in vivo activity against Plasmodium
vinckei and Plasmodium yoelii parasites [13,14].
Currently, there is no MB available globally that
complies with European Pharmacopoeia. To date, the
pharmaceutical use of MB has been stymied by contam-
ination with organic impurities and heavy metals with
recognized toxicity. Provence Technologies and its subsi-
diary, Provepharm, have conducted four years of research
that resulted in the first European Pharmacopoeia-grade
MB: ProveblueW. This drug was obtained from an innova-
tive synthetic and heavy-metal-free pathway using phar-
maceutical-grade reagents (patent application N°FR06/
06330, which has been extended to the international PCT
reference PCT/FR/2007/001193). The total concentration
of metals, Azure B (the most important impurity in MB)
and other impurities in ProveblueW is <20 ppm, <2%,
<0.5%, respectively. ProveblueW has in vitro anti-malarial
activity (mean IC50 = 3.62 nM) against 23 P. falciparum
strains that are resistant to other anti-malarial drugs [15].
No significant association was found between the Pro-
veblue IC50 and polymorphisms in the genes that are
involved in quinoline resistance, such as pfcrt, pfmdr1,
pfmdr2, pfmrp and pfnhe-1; furthermore, there is no
significant association between the Proveblue IC50
and the copy numbers of pfmdr1 and pfmdr2 [15].
While ProveblueW has in vitro antagonistic effects when
combined with chloroquine and additive effects when
combined with desethylamodiaquine against nine P.
falciparum strains, ProveblueW exhibited noticeable sy-
nergistic effects when combined with mefloquine and
quinine and high synergistic effects when combined
with dihydroartemisinin, the active metabolite of arte-
misinin derivatives [16].
Statins, the inhibitors of 3-hydroxy-3-methylglutaryl-
Coenzyme A reductase (HMG-CoA reductase) and a
family of lipid-lowering drugs, have in vitro anti-malarial
properties [17,18]. Atorvastatin (AVA), like the other
statins, is not a highly active blood schizonticidal anti-
malarial drug with IC50 values ranged from 2.5 to 12 μM
[17,18]. Its application in malaria chemotherapy would
be for adjuvant treatment. Moreover, AVA improved the
in vitro activity of mefloquine [19], quinine [20], dihy-
droartemisinin [21] and ProveblueW [16] at the plasma
concentrations expected in clinical observations in pa-
tients taking 80 mg of AVA daily (0.1 to 0.5 μM) [22].
However, AVA used alone failed to prevent death from
cerebral malaria or to affect the parasitaemia of infectedmice [23]. AVA combined with mefloquine led to a sig-
nificant delay in mouse death and had an effect on the
onset of cerebral malaria symptoms [24].
The objective of the present work was to evaluate the
in vivo efficacy of ProveblueW when combined with AVA
in a murine model of experimental cerebral malaria.
While animal models do not exactly reproduce human
malaria, they nevertheless exhibit some similarities to
human cerebral malaria, and the Plasmodium berghei
ANKA rodent parasite model is generally accepted as
valid for studying experimental cerebral malaria patho-
genesis [25,26].
Methods
Mice and experimental cerebral malaria
Forty female C57Bl6/N mice, six to seven weeks old
and weighing 18–22 g (Charles Rivers, France), were
infected on day 0 (D0) with P. berghei ANKA para-
sites by intraperitoneal (ip) inoculation. The inoculum
contained 105 parasitized erythrocytes extracted from
infected donor C57Bl6/N mice and diluted in 200 μl
normal saline. All animals were pathogen-free and were
housed under standard conditions, with unlimited ac-
cess to food and water. All efforts were made to mi-
nimize animal suffering. All experiments adhered to
French guidelines for animal research and were appro-
ved by the ethical committee of the Institut de Recher-
che Biomédicale des Armées - Antenne de Marseille
(Number 2007–09).
Except for the control group (8 mice), mice were trea-
ted daily when parasitaemia reached 0.1% by ip injection
with 40 mg/kg AVA for seven days (7 mice), 10 mg/kg
ProveblueW for five days (9 mice) or 40 mg AVA for
seven days combined with 10 mg/kg ProveblueW during
five days (10 mice). AVA calcium salt was dissolved in
1% dimethyl sulfoxyde (vol/vol) in 0.9% NaCl. The solu-
tion of 1% dimethyl sulfoxyde (vol/vol) in 0.9% NaCl was
ip administered to control mice (after previously eval-
uation of absence of effect in infected and non-infected
mice in comparison with 0.9% NaCl). ProveblueW was
dissolved in 0.9% NaCl.
Parasitaemia was determined daily using Giemsa-
stained thin blood smears collected from the tail vein.
Parasitaemia was calculated by the number of infected
red blood cells per 3,000 erythrocytes if >1% cells
were infected and per 10,000 erythrocytes if <1% cells
were infected. The animals were under daily supervi-
sion for clinical signs, neurological symptoms and weight.
Experimental cerebral malaria was diagnosed by clinical
signs based on a simplified SHIRPA protocol [27] with
at least two symptoms in at least two of the three
different groups: 1) alteration of autonomous function
(piloerection, defecation, urination, respiration rate); 2) al-
teration of muscle tone and strength (grip strength, body
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lysis (mono-, hemi-, para-, or tetraplegia), deviation of
the head, convulsions and coma.
Statistical analysis
The data were analysed using R softwareW (version
2.10.1). Survival analyses were performed by the Kaplan-
Meier log rank test. The comparison of medians between
multiple groups was analysed by the Kruskal-Wallis test.
The comparison of medians between two groups was
analysed by the Mann–Whitney test. A difference was
considered significant when P-values were less than 0.05.
Results
In the control group, all the mice died before D10, with
specific signs of cerebral malaria and parasitaemia <10.5%
(6.7-10.5%) (Figure 1). The mice treated with 40 mg/kg
AVA died between D5 and D9 (29% of the experimental
group) with specific cerebral malaria symptoms and para-
sitaemia (5.7-6.8%) or between D18 and D24 with anaemia
and parasitaemia (94.2-98.4%). In the group of mice
treated with 10 mg/kg ProveblueW, one mouse (11%) had
recurrent parasites at D5 and died at D16 (50.0% parasi-
taemia), and another had recurrent parasites at D11 and
died at D25 (91.7% parasitaemia). These two mice died
with no specific signs of cerebral malaria. After two days
of treatment with ProveblueW, no parasite was detectable
by blood smear. At D45, the surviving mice had no para-
sites. In the group of mice treated with 40 mg/kg AVA
combined with 10 mg/kg ProveblueW, one mouse (10%)
had recurrent parasites at D10 and died at D14 (6.6%
parasitaemia) with specific signs of cerebral malaria. At
D45, the surviving mice had no parasites.
Discussion
Treatment with AVA alone did not demonstrate an effect
significantly different from no treatment (p = 0.0573). AllFigure 1 Survival curve of C57Bl6/N mice infected on day 0 (D0) with
atorvastatin (AVA) for seven days, 10 mg/kg ProveblueW for five days
ProveblueW for five days.the mice treated by AVA alone died. These results confirm
that in an experimental cerebral malaria model, therapeu-
tic ip AVA treatment, similar to other statins, shows no ef-
fect on the incidence of cerebral malaria [23,24,28,29].
The pathogenesis of cerebral malaria in the murine model
relies solely on the inflammatory response, unlike the pa-
thogenesis of human cerebral malaria. Indeed, the cyto-
adherence phenomenon does not exist in P. berghei mice
infections [30,31]. AVA strongly protects endothelial
cell against P. falciparum-induced collateral damages, cell
apoptosis and endothelial barrier permeabilization [32].
AVA can be used to reduce P. falciparum cytoadherence
to endothelial cells; cytoadherence and the inflammatory
burst are the key events of pathogenesis in severe human
malaria. In mice with P. berghei ANKA cerebral malaria,
lovastatin reduces pro-inflammatory cytokines in the brain
and prevents cognitive impairment [33].
Treatment with ProveblueW, or a combination of
ProveblueW and AVA, significantly reduced or prevented
cerebral malaria (p = 0.0011 and 0.0002, respectively).
A ProveblueW regimen of 10 mg/kg resulted in a 75%
survival rate. This dosage is safe in children treated
with methylene blue that was non-compliant with the
European Pharmacopoeia [34,35]. Methylene blue at
doses ranged from 12 mg/kg/day to 24 mg/kg/day for
three days were administered to children with uncompli-
cated malaria in Burkina-Faso. Only one mouse died in
the AVA and ProveblueW combination treatment group.
The combination of ProveblueW and AVA was more ef-
fective than AVA alone in the experimental cerebral mal-
aria mouse model (p = 0.0012). Although there was only
one death with AVA plus ProveblueW treatment (10%) ver-
sus two deaths (22%) with ProveblueW alone, the effect on
cerebral malaria was not significant (p = 0.283). Thus, the
efficacy of the combination may be due to the effect of
ProveblueW, not as a result of a synergism between the
two compounds. The dose of 10 mg/kg of ProveblueW forPlasmodium berghei ANKA parasites and treated with 40 mg/kg
or 40 mg atorvastatin for seven days combined with 10 mg/kg
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seems to be too high to show synergistic effects in com-
bination with AVA. Combination with lower doses of
ProveblueW should be evaluated. ProveblueW or AVA plus
ProveblueW treatments are more effective than AVA and
mefloquine combinations, which can delay mouse death
and/or the onset of cerebral malaria but do not prevent
death by anaemia [24]. The role of AVA in inhibiting
cytoadherence in humans is not evaluable in mice, as this
phenomenon does not exist in the P. berghei murine ma-
laria model.
For the first time, the present work demonstrated
the high efficacy of ProveblueW in preventing cerebral
malaria. Another advantage of ProveblueW as an anti-
malarial drug is that MB inhibits the maturation and
transmission of gametocytes [36-38]. Of 44 compounds
provided by Medicines for Malaria Venture, MB was the
most active compound and reduced gametocyte viability
with an IC50 value of 12 nM [39]. These results confirm
the therapeutic potential of ProveblueW, a new MB for-
mulation with limited organic impurities and toxic heavy
metals that could be integrated into the pipeline of anti-
malarial combination therapy [40]. AVA alone appears
to possess limited use for preventing cerebral malaria.
However, ProveblueW and AVA have different and com-
plementary properties (effects on asexual stages, gameto-
cyte maturation and transmission, cytoadherence, and
pro-inflammatory cytokine levels), which makes them in-
teresting partners for future investigation using combin-
ation therapy. Combination of AVA with lower doses of
ProveblueW should be evaluated to show potential syner-
gistic effects in cerebral malaria prevention. The present
work demonstrated the high efficacy of ProveblueW in
preventing cerebral malaria. The efficacy of ProveblueW
and combination of AVA and ProveblueW should be eval-
uated in treating murine cerebral malaria.
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